Traws Pharma (NASDAQ:TRAW) Posts Earnings Results

Traws Pharma (NASDAQ:TRAW – Get Free Report) announced its earnings results on Monday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03, Zacks reports.

Traws Pharma Price Performance

Shares of TRAW stock traded up $0.01 on Monday, hitting $0.26. 210,244 shares of the company’s stock were exchanged, compared to its average volume of 915,880. Traws Pharma has a 12 month low of $0.22 and a 12 month high of $3.23. The stock has a market cap of $4.00 million, a P/E ratio of -0.15 and a beta of 1.67. The company has a 50 day moving average of $0.43 and a 200 day moving average of $1.07.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TRAW. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Traws Pharma in a report on Tuesday, August 18th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $1.00.

Check Out Our Latest Stock Report on TRAW

About Traws Pharma

(Get Free Report)

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Read More

Earnings History for Traws Pharma (NASDAQ:TRAW)

Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.